Verona Pharma News and Resources
Nov 19, 2024 · Stay updated with Verona Pharma's latest news and resources. Access materials to follow our progress in developing treatments for respiratory diseases and understand our journey and impact in tackling these conditions.
News & SEC Filings - Verona Pharma
3 days ago · Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Verona Pharma Announces US FDA Approval of Ohtuvayre™ …
Jun 26, 2024 · LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Verona Pharma Press Releases & Updates
Nov 19, 2024 · LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.
Verona Pharma | Innovative Respiratory Treatments
3 days ago · Verona Pharma develops novel treatments like ensifentrine in COPD. Future development is focused on chronic lung diseases such as COPD, asthma, and cystic fibrosis. Explore our advancements, patient insights, and latest investor news
Verona Pharma Reports Third Quarter 2024 Financial Results and …
Nov 4, 2024 · LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2024, and provides a corporate update.
Verona Pharma Announces $650 Million Strategic Financing with …
May 9, 2024 · The agreements provide non-dilutive capital and additional financial flexibility ahead of Verona Pharma’s planned US launch of ensifentrine and will support the Company’s continued growth.
Investor Relations | Verona Pharma
3 days ago · Learn about Verona Pharma's innovative respiratory treatments and latest financial updates. Explore our investor presentation, recent results, and news for insights into our progress and company performance.
Verona Pharma to Report Third Quarter 2024 Financial Results and ...
Oct 21, 2024 · LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT ...
Verona Pharma to Present at Jefferies London Healthcare …
Nov 5, 2024 · LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference